Open AccessDeprescribing and Optimal Selection of Proton Pump Inhibitors (Contributions of the 26th United Russian Gastroenterology Week)
Author(s) -
В. Т. Ивашкин,
И. В. Маев,
А. С. Трухманов,
А. А. Шептулин,
В. И. Симаненков,
Т. Л. Лапина,
И. Б. Хлынов,
Н. Н. Дехнич,
Оlga D. Lopina,
О. П. Алексеева,
Н. В. Корочанская,
М. Ф. Осипенко,
П. В. Павлов,
С. С. Пирогов,
Г. Н. Тарасова,
Ю. П. Успенский,
Д. Н. Андреев,
Д. Н. Румянцева
Publication year - 2020
Publication title -
rossijskij žurnal gastroènterologii, gepatologii, koloproktologii
Language(s) - English
Resource type - Journals
eISSN - 2658-6673
pISSN - 1382-4376
DOI - 10.22416/1382-4376-2020-30-6-7-18
Subject(s) - deprescribing , medicine , regimen , rabeprazole , proton pump inhibitor , lansoprazole , intensive care medicine , polypharmacy , gastroenterology , pharmacology , omeprazole
Aim . Presentation of the Forum “Deprescribing and optimal selection of proton pump inhibitors” held in Moscow on 29 September 2020 during the 26th United Russian Gastroenterology Week. Key points . The Forum was aimed at discussing issues associated with improving the proton pump inhibitor (PPIs) therapy in treatment and prevention of acid-related diseases and upper gastrointestinal tract (GIT) disorders induced by non-steroidal anti-inammatory drugs (NSAIDs) and antiplatelet medications. Deprescribing is considered to be an eective strategy of a motivated reduction of the PPI dosage, duration of therapy and the patient’s transfer from a regular to on-demand intake regimen. The choice of PPI may condition an optimal therapy for acid-related diseases. Conclusion . PPIs prevail in therapies for acid-related diseases and NSAID-induced upper GIT lesions. PPI deprescribing should be a strategy of choice if medically indicated. A non-enzymatic metabolism, high acid suppression, stable antisecretory eect from day 1 of therapy and cytoprotective action justify the application of rabeprazole (Pariet®) for optimising therapies for acid-related diseases and implementing the deprescribing strategy.